Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q2 2026 · 10-Q
Revenue$108.02M$108.02M+405.7% vs Q2 2025 Net Income$22.71M$22.71MN/M vs Q2 2025 EPS Diluted$0.43$0.43N/M vs Q2 2025 Operating Income$29,263,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$62,998,000N/M Margins · derivedOperating margin27.1%+323.3 pt vs Q2 2025
Net margin21.0%+352.8 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end